Published in J Clin Invest on September 01, 2015
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature (2016) 1.56
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell (2016) 1.44
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 1.39
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol (2016) 1.20
Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest (2015) 1.04
Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol (2015) 1.02
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol (2016) 0.96
A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. Immunity (2017) 0.85
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80
Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. J Interferon Cytokine Res (2016) 0.79
Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe? Biomedicines (2016) 0.78
Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy (2017) 0.76
Immunological battlefield in gastric cancer and role of immunotherapies. World J Gastroenterol (2016) 0.76
EMT and inflammation: inseparable actors of cancer progression. Mol Oncol (2017) 0.75
Systematic evaluation of immune regulation and modulation. J Immunother Cancer (2017) 0.75
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J Exp Pharmacol (2016) 0.75
Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer. Trends Mol Med (2017) 0.75
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3(+) regulatory T cells in murine colon cancer. Oncoimmunology (2017) 0.75
Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol (2017) 0.75
Mesothelioma response to carbon nanotubes is associated with an early and selective accumulation of immunosuppressive monocytic cells. Part Fibre Toxicol (2016) 0.75
Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity. Front Immunol (2017) 0.75
Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. Mediators Inflamm (2017) 0.75
Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. Cancer Res (2017) 0.75
Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther (2016) 0.75
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer (2017) 0.75
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. J Immunother Cancer (2017) 0.75
Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response. Sci Rep (2017) 0.75
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest (2017) 0.75
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget (2017) 0.75
Energy metabolic pathways control the fate and function of myeloid immune cells. J Leukoc Biol (2017) 0.75
Cancer-related inflammation. Nature (2008) 34.21
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 21.56
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 7.26
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res (2007) 6.60
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell (2012) 5.77
Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 5.47
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65
Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell (2012) 4.58
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 4.53
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res (2010) 4.25
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol (2008) 3.91
The cellular and molecular origin of tumor-associated macrophages. Science (2014) 3.89
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2010) 3.86
Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 3.75
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood (2004) 3.59
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 3.57
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev (2010) 3.56
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell (2014) 3.52
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature (2014) 3.31
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol (2008) 3.30
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother (2011) 2.97
Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 2.96
Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature (2014) 2.91
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2009) 2.90
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
The microbiome and cancer. Nat Rev Cancer (2013) 2.86
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res (2005) 2.83
Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell (2014) 2.78
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 2.77
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature (1995) 2.61
Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell (2014) 2.61
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51
Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol (2011) 2.45
Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A (2012) 2.42
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell (2014) 2.40
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood (2010) 2.38
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity (2015) 2.29
Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood (2009) 2.26
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res (2011) 2.20
Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature (2008) 2.18
Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15
Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One (2012) 2.14
Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol (2014) 2.14
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A (2011) 2.08
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature (2015) 2.04
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol (2014) 2.01
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 2.01
Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene (2005) 2.00
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest (2013) 1.94
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol (2010) 1.94
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 1.92
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother (2012) 1.87
Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol (2007) 1.87
Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1.69
Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol (2009) 1.68
Control of immune response by amino acid metabolism. Immunol Rev (2010) 1.63
Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe (2013) 1.62
Part I: Vaccines for solid tumours. Lancet Oncol (2004) 1.61
Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep (2012) 1.59
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood (2005) 1.56
Common cancer biomarkers. Cancer Res (2006) 1.56
Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev (2007) 1.55
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood (2011) 1.47
Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics (2013) 1.39
Role of arginine metabolism in immunity and immunopathology. Immunobiology (2007) 1.33
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31
Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res (2005) 1.28
Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol (2011) 1.25
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood (2009) 1.20
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res (2009) 1.10
Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol (2014) 1.08
Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer (2006) 1.07
Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol (2011) 1.07
miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity (2013) 1.07
Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol (2011) 1.03
Melanoma-restricted genes. J Transl Med (2004) 1.03
Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol (2011) 1.02
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine (2010) 1.02
Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev (2011) 1.01
Retracted High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res (2012) 1.01
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res (2009) 1.00
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res (2008) 0.99
The pros and cons of chemokines in tumor immunology. Trends Immunol (2012) 0.99
Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin Cancer Biol (2007) 0.97
Cancer vaccines: pessimism in check. Nat Med (2004) 0.97
Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest (2014) 0.96
Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom (2014) 0.95
Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid (2007) 0.95
Measurement of myeloid cell immune suppressive activity. Curr Protoc Immunol (2010) 0.94
Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes. Cancer Res (2004) 0.90
Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol (2010) 0.89
Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood (2013) 0.89
Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest (2006) 0.86
Role of microRNAs in HTLV-1 infection and transformation. Mol Aspects Med (2010) 0.85
Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis (2009) 0.84
Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. Immunol Invest (2012) 0.84
Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. J Virol (2014) 0.83
Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biol (2012) 0.83
Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. Neoplasia (2012) 0.83
Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol (2009) 0.82
L-glutamine is a key parameter in the immunosuppression phenomenon. Biochem Biophys Res Commun (2012) 0.82
Part II: Vaccines for haematological malignant disorders. Lancet Oncol (2004) 0.81
Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. Biomatter (2014) 0.81
Clinical and histological healing of a new collagen matrix in combination with the coronally advanced flap for the treatment of Miller class-I recession defects: an experimental study in the minipig. J Clin Periodontol (2011) 0.81
Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom (2014) 0.80
Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients. Am J Pathol (2013) 0.80
The transcriptional response in human umbilical vein endothelial cells exposed to insulin: a dynamic gene expression approach. PLoS One (2010) 0.78